Jan 17, 2023
Oncotelic Announces the launch of PDAO token
Dec 28, 2022
Oncotelic Issues Year End Message to Shareholders
Dec 19, 2022
Oncotelic Presents Clinical Data of Confirming TGF-β2 as the appropriate target for gliomas at JCA-AACR Meeting 2022
Nov 30, 2022
Oncotelic Publishes SNO 27th Annual Meeting Presentation Materials
Nov 21, 2022
Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results
Nov 16, 2022
Oncotelic Publishes SITC Meeting 2022 Presentation Materials
Nov 08, 2022
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric Gliomas
Oct 12, 2022
Oncotelic Awarded BARDA Funding for Development of OT-101 for long COVID
Oct 06, 2022
Oncotelic Announces Formation of Animal Health Division
Sep 28, 2022
Oncotelic Presenting Data for OT101 Against Pancreatic Cancer (PDAC) at the SITC 37th Annual Meeting
1
2
3
4
5
6
7
8
<<
<
>
>>
Copyright © 2021 Oncotelic Inc., a TGF ImmunoOncology Company. All rights reserved.
Privacy